Albireo Pharma Inc (ALBO) Receives a Buy from Cowen & Co.

By Austin Angelo

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Albireo Pharma Inc (NASDAQ: ALBO). The company’s shares opened today at $29.47.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.5% and a 56.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Albireo Pharma Inc is a Strong Buy with an average price target of $68.33.

See today’s analyst top recommended stocks >>

Based on Albireo Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.6 million. In comparison, last year the company had a GAAP net loss of $6.18 million.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALBO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.